These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 14993107)

  • 21. Effect of peptides on the inactivation of tissue plasminogen activator by plasminogen activator inhibitor-1 and on the binding of tissue plasminogen activator to endothelial cells.
    Wittwer AJ; Sanzo MA
    Thromb Haemost; 1990 Oct; 64(2):270-5. PubMed ID: 2125376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
    van Giezen JJ; Boon GI; Jansen JW; Bouma BN
    Thromb Haemost; 1993 Apr; 69(4):381-6. PubMed ID: 8497851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pimaradienoic acid inhibits vascular contraction and induces hypotension in normotensive rats.
    Tirapelli CR; dos Anjos Neto Filho M; Bonaventura D; Melo MC; Ambrosio SR; de Oliveira AM; Bendhack LM; da Costa FB
    J Pharm Pharmacol; 2008 Apr; 60(4):453-9. PubMed ID: 18380917
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of flutamide on systemic and renal hemodynamics in Zucker diabetic rats: paradoxic renal vasodilator response to endothelin-1 and TXA2 receptor activation in female sex.
    Ajayi AA; Fidelis P
    J Cardiovasc Pharmacol; 2006 Nov; 48(5):191-8. PubMed ID: 17110800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo effects of endothelin on the renal microcirculation.
    Bloom IT; Bentley FR; Wilson MA; Garrison RN
    J Surg Res; 1993 Apr; 54(4):274-80. PubMed ID: 8331921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins.
    Wiesbauer F; Kaun C; Zorn G; Maurer G; Huber K; Wojta J
    Br J Pharmacol; 2002 Jan; 135(1):284-92. PubMed ID: 11786505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction.
    Chew DK; Conte MS; Khalil RA
    J Vasc Surg; 2004 Nov; 40(5):1001-10. PubMed ID: 15557917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator.
    Shenkman B; Livnat T; Budnik I; Tamarin I; Einav Y; Martinowitz U
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):729-33. PubMed ID: 22918041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kavain attenuates vascular contractility through inhibition of calcium channels.
    Martin HB; McCallum M; Stofer WD; Eichinger MR
    Planta Med; 2002 Sep; 68(9):784-9. PubMed ID: 12357387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tissue-plasminogen activator restores muscle flap perfusion in the rat.
    Krapohl BD; Siemionow M; Zins JE
    J Hand Surg Am; 1999 Sep; 24(5):1036-44. PubMed ID: 10509283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal cortical and medullary microvascular blood flow autoregulation in rat.
    Harrison-Bernard LM; Navar LG
    Kidney Int Suppl; 1996 Dec; 57():S23-9. PubMed ID: 8941918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epsilon-aminocaproic acid inhibition of fibrinolysis in vitro: should the 'therapeutic' concentration be reconsidered?
    Nielsen VG; Cankovic L; Steenwyk BL
    Blood Coagul Fibrinolysis; 2007 Jan; 18(1):35-9. PubMed ID: 17179824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects and mechanism of tissue-type plasminogen activator and plasminogen activator inhibitor on vascular smooth muscle cell proliferation.
    Xiaoli M; Wenying H; Mingpeng S
    Int J Cardiol; 1998 Oct; 66 Suppl 1():S57-64; discussion S65. PubMed ID: 9951803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Blood clearance and activity of erythrocyte-coupled fibrinolytics.
    Ganguly K; Krasik T; Medinilla S; Bdeir K; Cines DB; Muzykantov VR; Murciano JC
    J Pharmacol Exp Ther; 2005 Mar; 312(3):1106-13. PubMed ID: 15525799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Pharmacokinetic and Pharmacodynamic Investigation of an ε-Aminocaproic Acid Regimen Designed for Cardiac Surgery With Cardiopulmonary Bypass.
    Strauss ER; Dahmane E; Judd M; Guo D; Williams B; Meyer M; Gammie JS; Taylor B; Mazzeffi MA; Gobburu JVS; Tanaka KA
    J Cardiothorac Vasc Anesth; 2021 Feb; 35(2):406-417. PubMed ID: 32811752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pyruvate and cilostazol protect cultured rat cortical pericytes against tissue plasminogen activator (tPA)-induced cell death.
    Kim HN; Kim TY; Yoon YH; Koh JY
    Brain Res; 2015 Dec; 1628(Pt B):317-326. PubMed ID: 26111647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LRP and alphavbeta3 mediate tPA activation of smooth muscle cells.
    Akkawi S; Nassar T; Tarshis M; Cines DB; Higazi AA
    Am J Physiol Heart Circ Physiol; 2006 Sep; 291(3):H1351-9. PubMed ID: 16489109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mycoplasma cells stimulate in vitro activation of plasminogen by purified tissue-type plasminogen activator.
    Tarshis M; Morag B; Mayer M
    FEMS Microbiol Lett; 1993 Jan; 106(2):201-4. PubMed ID: 8454185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. tPA regulates pulmonary vascular activity through NMDA receptors.
    Nassar T; Bdeir K; Yarovoi S; Fanne RA; Murciano JC; Idell S; Allen TC; Cines DB; Higazi AA
    Am J Physiol Lung Cell Mol Physiol; 2011 Sep; 301(3):L307-14. PubMed ID: 21571905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Features of the effect of tissue and urokinase-type plasminogen activators on vascular tone].
    Sergeev IIu
    Dokl Akad Nauk; 1997 Oct; 356(4):555-7. PubMed ID: 9424175
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.